‘New Dawn’ for Aldosterone as a Drug Target in Hypertension?
Once-daily treatment with the selective aldosterone synthase inhibitor lorundrostat (Mineralys Therapeutics) safely and significantly reduced blood pressure in adults with uncontrolled hypertension in a phase 2 randomized clinical trial. Eight weeks after adding lorundrostat (50 mg or 100 mg once daily) or placebo to background therapy, the drug reduced automated office sitting systolic blood pressure … Read more